Claritev (NYSE:CTEV) CEO Travis Dalton Purchases 4,500 Shares of Stock

Claritev (NYSE:CTEV) CEO Travis Dalton purchased 4,500 shares of the company’s stock in a transaction that occurred on Thursday, August 27th. The stock was acquired at an average cost of $38.81 per share, with a total value of $174,645.00. Following the transaction, the chief executive officer directly owned 50,372 shares of the company’s stock, valued at approximately $1,954,937.32. This represents a 9.81% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Travis Dalton also recently made the following trade(s):

• On Friday, August 28th, Travis Dalton acquired 1,950 shares of Claritev stock. The shares were bought at an average cost of $38.48 per share, for a total transaction of $75,036.00.

Claritev Trading Up 0.6%

NYSE CTEV opened at $39.63 on Tuesday. Claritev has a 1-year low of $11.50 and a 1-year high of $74.07. The company has a market capitalization of $671.73 million, a price-to-earnings ratio of -2.33 and a beta of 0.74. The stock’s 50 day moving average is $31.43 and its two-hundred day moving average is $24.87.

Claritev (NYSE:CTEV) last issued its earnings results on Friday, August 7th. The company reported $1.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($4.10) by $5.51. The company had revenue of $257.48 million during the quarter. On average, analysts predict that Claritev will post -15.13 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Piper Sandler restated an “overweight” rating and issued a $73.00 target price on shares of Claritev in a research note on Wednesday, August 12th. Barclays reiterated an “overweight” rating and set a $40.00 target price (up from $28.00) on shares of Claritev in a research report on Thursday, August 20th. Wall Street Zen raised shares of Claritev from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Claritev in a research report on Wednesday, June 24th. Finally, Zacks Research upgraded shares of Claritev from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 13th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $44.83.

Institutional Trading of Claritev

Several hedge funds have recently modified their holdings of CTEV. Bank of New York Mellon Corp increased its holdings in shares of Claritev by 2.5% in the first quarter. Bank of New York Mellon Corp now owns 18,111 shares of the company’s stock valued at $296,000 after purchasing an additional 447 shares in the last quarter. State of Wyoming bought a new position in Claritev in the 4th quarter valued at $25,000. Ameritas Investment Partners Inc. bought a new position in Claritev in the 3rd quarter valued at $42,000. Legal & General Group Plc acquired a new stake in shares of Claritev in the 3rd quarter valued at $45,000. Finally, Invesco Ltd. increased its stake in shares of Claritev by 4.8% in the 4th quarter. Invesco Ltd. now owns 22,802 shares of the company’s stock valued at $975,000 after buying an additional 1,044 shares during the period. 87.15% of the stock is owned by institutional investors.

About Claritev

Claritev is a healthcare technology, data and insights company focused on improving affordability,  transparency and quality. Led by deeply experienced associates, data scientists, and innovators, Claritev provides tech-enabled solutions and services fueled by multiple data sources from over 40 years of claims repricing. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design.